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Abstract
EFSA was asked to deliver a scientiﬁc opinion regarding the effect on public health of a possible increase
of the maximum level (ML) for ‘aﬂatoxin total’ (AFT; sum of aﬂatoxin B1, aﬂatoxin B2, aﬂatoxin G1 and
aﬂatoxin G2) from 4 to 10 lg/kg in peanuts and processed products thereof. Aﬂatoxins are genotoxic and
cause hepatocellular carcinomas in humans. The Panel on Contaminants in the Food Chain (CONTAM
Panel) evaluated 8,085 samples of peanuts and 472 samples of peanut butter, with > 60% left-censored.
The mean concentration of AFT in peanuts was 2.65/3.56 lg/kg (lower bound (LB)/upper bound (UB))
with a maximum of 1,429 lg/kg. The mean concentration in peanut butter was 1.47/1.92 lg/kg (LB/UB)
with a maximum of 407 lg/kg. Peanut oil was not included since all data were left-censored and the ML
does not apply for oil. Exposure was calculated for a ‘Current ML’ and ‘Increased ML’ scenario, and mean
chronic exposure estimates for consumers only, amounted to 0.04–2.74 ng/kg body weight (bw) per day
and 0.07–4.28 ng/kg bw per day, respectively. The highest exposures were calculated for adolescents
and other children. The CONTAM Panel used the cancer potencies estimated by the Joint FAO/WHO
Expert Committee on Food Additives for the risk characterisation. Under the scenario of the current ML,
the cancer risk was estimated to range between 0.001 and 0.213 aﬂatoxin-induced cancers per 100,000
person years. Under the scenario of the increased ML, it ranged between 0.001 and 0.333 aﬂatoxin-
induced cancers per 100,000 person years. Comparing these data calculated under the current ML
scenario with the yearly excess cancer risk of 0.014 shows a higher risk for consumers of peanuts and
peanut butter in some surveys. The calculated cancer risks indicate that an increase of the ML would
further increase the risk by a factor of 1.6–1.8.
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Summary
Following a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to deliver a scientiﬁc opinion on the effect on public health of a possible
increase of the maximum level (ML) for ‘aﬂatoxin total’ (AFT) from 4 to 10 lg/kg in peanuts and
processed products thereof, intended for direct human consumption or used as an ingredient in
foodstuffs. The assessment should include vulnerable groups of the population and take the
consumption patterns within the European Union (EU) into account.
Aﬂatoxins are mycotoxins produced primarily by the fungi Aspergillus ﬂavus and Aspergillus
parasiticus. A. parasiticus produces aﬂatoxin B1 (AFB1), aﬂatoxin B2 (AFB2), aﬂatoxin G1 (AFG1) and
aﬂatoxin G2 (AFG2), whereas A. ﬂavus mainly produces AFB1 and AFB2. However, A. ﬂavus isolates
producing AFG1 and AFG2 also have been identiﬁed. These fungi are especially found in areas with a
hot and humid climate. AFB1 is the most frequently found aﬂatoxin in contaminated samples and the
three others are generally not reported in the absence of AFB1. AFT refers to the sum of these four
aﬂatoxins.
Aﬂatoxins have primarily been detected in imported foods such as peanuts, tree nuts, dried fruit,
spices, crude oil, cocoa beans, maize and rice. Processes such as heating, roasting and baking can reduce
the levels of aﬂatoxins but cannot completely eliminate the toxins. Extraction and reﬁning of oil can
reduce the levels of aﬂatoxins to less than 1 lg/kg even from highly contaminated samples of peanuts.
AFB1 is a genotoxic and potent liver carcinogen in experimental animals and humans. In
experimental animals, AFG1 is also carcinogenic, whereas there is limited evidence for carcinogenicity
of AFB2 and inadequate evidence for carcinogenicity of AFG2.
EFSA assessed the toxicology of aﬂatoxins in 2007 and the most recent evaluation was carried out
by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 2016. Given the short deadline
of this request, no new toxicological evaluation was performed by the CONTAM Panel. Therefore, the
CONTAM Panel decided to use the cancer potencies estimated by JECFA. The cancer potencies for an
AFB1 exposure of 1 ng/kg body weight (bw) per day (in 100,000 person years) were estimated to be
0.017 (mean estimate) for hepatitis B surface antigen negative (HBsAg–) individuals and 0.269 for
HBsAg+ individuals using model averaging. The 95% UB potency estimates were 0.049 and 0.562,
respectively. No reference point or cancer potency has been identiﬁed for AFT, AFB2, AFG1 or AFG2 in
previous assessments. Considering that AFB1 is the major contributor to the exposure, the CONTAM
Panel used a conservative approach and evaluated the aﬂatoxins as a group and applied the cancer
potencies calculated for AFB1 to AFT.
Occurrence data on aﬂatoxins in peanuts, peanut butter and peanut oil were available in the EFSA
Chemical Occurrence database. Only samples in which AFB1, AFB2, AFG1 and AFG2 were analysed,
were used in the assessment. In total, 34,324 analytical results for AFB1, AFB2, AFG1 and AFG2 were
taken into account. These correspond to 8,581 samples, of which 8,095 were peanuts, 472 samples
were peanut butter and 14 were peanut oil. Most of the samples had AFT concentrations less than
10 lg/kg. About 66% of the data were provided by two countries. Due to time constraints, it was not
feasible to issue a complementary call for data.
The highest concentrations of AFT were found in peanuts with a mean value of 2.65/3.56 lg/kg
(lower bound (LB)/upper bound (UB)). Most of the samples (87%) were left-censored with a maximum
concentration of 1,429 lg/kg. Seven per cent of the samples had a concentration above the ML of
4 lg/kg. Concentrations of AFT in peanut butter were lower with a mean value of 1.47/1.92 lg/kg
(LB/UB) and a maximum of 407 lg/kg. Five per cent of the samples had a concentration above the ML
of 4 lg/kg and 64% of the samples were left-censored. All 14 samples of peanut oil were
left-censored. Because the ML of 4 lg/kg does not apply to crude or reﬁned vegetable oil, peanut oil
was not included in the exposure assessment.
Contribution of the individual aﬂatoxins to the AFT concentration varied but the major contributor
was AFB1 representing 61% of the MB AFT concentration for samples containing less than 1 lg/kg,
and up to 78% for samples containing more than 10 lg/kg.
Consumers of peanuts and peanut butter represent on average 7% (range: 0–36%) of the total
population, so the CONTAM Panel concluded that exposure estimates, for consumers only, were the
most adequate.
No data were available regarding consignments that were not shipped to the EU due to levels
exceeding the current ML of 4 lg/kg but would have been placed on the EU market if a higher ML was
in place. Therefore, the CONTAM Panel made a simulation by bootstrapping instead. It is anticipated
that changing the ML from 4 to 10 lg/kg for peanuts will increase the mean LB estimates by a factor
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of 1.75 and the mean UB estimates by a factor of 1.56. Such a simulation could not be carried out for
peanut butter due to few samples above 4 lg/kg, but it was assumed that the factor for peanut butter
would be proportional to the factor for peanuts. The bootstrapping approach relied on the assumption
that the proportion of non-compliant samples (based on the reported data) would remain the same
after an increase of the ML.
Chronic dietary exposure was calculated for two scenarios namely a ‘Current ML’ and ‘Increased ML’
scenario. The current scenario represents exposure to the current situation with an ML of 4 lg/kg,
using the mean occurrence values for AFT in peanuts and peanut butter as reported. The ‘Increased
ML’ scenario represents exposure to a simulated market situation with an ML of 10 lg/kg. In this
scenario, the mean occurrence values for AFT in both peanuts and peanut butter were multiplied with
the calculated increase factors.
Under the ‘Current ML’ scenario, mean chronic exposure estimates, for consumers only, ranged
from 0.04 (lowest LB estimate) to 2.74 (highest UB estimate) ng/kg bw per day. If the ML is changed
to 10 lg/kg, the exposure estimates increased to 0.07–4.28 ng/kg bw per day, respectively. The
highest exposures were calculated for adolescents and other children.
Due to the low number of consumers in most dietary surveys and age classes, a reliable exposure
assessment for highly exposed consumers was not possible. Approximate estimations for the adult
population indicated that exposure of high consumers may be two to four times higher compared to
the exposure of average consumers.
Based on the cancer potencies estimated by JECFA in 2016, the CONTAM Panel estimated the
cancer risk based on the mean cancer potency estimates and a prevalence of HBsAg+ of 0.01%, as
well as on the UB potency estimates and a prevalence of HBsAg+ of 5.61%. Under the scenario of the
current ML, the cancer risk was estimated to range between 0.001 and 0.213 aﬂatoxin-induced
cancers per year per 100,000 persons. Under the scenario of the increased ML, it ranged between
0.001 and 0.333 aﬂatoxin-induced cancers per year per 100,000 persons.
According to the WHO Guideline for drinking-water quality, an excess lifetime cancer risk of 10–5 or
less is considered to be of low risk for public health and, assuming a lifetime expectancy of 70 years,
this corresponds to a yearly excess cancer risk of 0.014 additional cancer cases per 100,000 subjects.
Comparing the aﬂatoxin-induced cancers calculated under the current ML scenario with this yearly
excess cancer risk, a higher risk for consumers of peanut and peanut butter is identiﬁed in some
surveys. The calculated cancer risks indicate that an increase of the ML would further increase the risk
by a factor of 1.6–1.8.
The CONTAM Panel recommends that a full risk assessment should be carried out considering the
observation of elevated aﬂatoxin levels in some food commodities originating from European countries
and that the last full risk assessment by the CONTAM Panel was carried out in 2007. Knowledge on
contamination levels of consignments that were not shipped to the EU due to exceedance of the
current ML but would have been shipped if a higher ML was in place, would be needed when
assessing the effect on the risk for public health of a possible increase of an ML in the future.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
In Codex Alimentarius, and more speciﬁc in the Codex Committee on Contaminants in Food (CCCF),
discussions on a maximum level (ML) and associated sampling plan for ‘aﬂatoxin total’ (AFT) in ready-
to-eat peanuts are ongoing.
At the 11th session of CCCF in April 2017, it was concluded to request comments on the suggested
MLs of 10 or 15 lg/kg for AFT in ready-to-eat peanuts.
In preparation of the 11th session of CCCF, the EU had agreed to a position1 whereby the EU
objected to the proposed level of 15 lg/kg for the reasons outlined in the position.
As one of the proposed MLs (i.e. 10 lg/kg for AFT in ready-to-eat peanuts) is higher than the
current EU ML of 4 lg/kg for AFT in ready-to-eat peanuts, it is necessary that the European Food
Safety Authority (EFSA) assesses if the increase of the current EU ML of 4 lg/kg for AFT in peanuts
and processed products thereof, intended for direct human consumption or use as an ingredient in
foodstuffs to 10 lg/kg of AFT would not result in an unacceptable increase of the risk for public health
taking into account vulnerable groups of the population and the EU consumption patterns.
The ﬁnal possible acceptance by the EU of the ML of 10 lg/kg of AFT in ready-to-eat peanuts in
Codex Alimentarius Commission shall depend on the outcome of the abovementioned EFSA risk
assessment. Speciﬁc reference is made to the EFSA risk assessment in the EU position in preparation
to the 12th Session of the CCCF.2
1.1.2. Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority to assess the effect on public health of a possible increase of the ML
for AFT from 4 to 10 lg/kg in peanuts and processed products thereof, intended for direct human
consumption or use as an ingredient in foodstuffs taking into account vulnerable groups of the
population and the EU consumption patterns.
1.2. Interpretation of the Terms of Reference
In order to fulﬁl the terms of reference, the EFSA Panel on Contaminants in the Food Chain
(CONTAM) concluded that this opinion should comprise an:
a) estimation of the inﬂuence of a possible increase of the ML for AFT, from 4 to 10 lg/kg in
peanuts and processed products thereof, intended for direct human consumption or use as an
ingredient in foodstuffs, on the dietary exposure of the EU population to AFT from such
peanuts, including the consumption patterns of speciﬁc groups of the population if appropriate;
b) assessment of the human health risks for the EU population, including speciﬁc groups of the
population if appropriate, as the consequence of the estimated dietary exposure.
A re-evaluation of the toxicological properties of aﬂatoxins is beyond the scope of this assessment.
1.3. Supporting information for the assessment
Aﬂatoxins are mycotoxins produced primarily by the fungi Aspergillus ﬂavus and Aspergillus
parasiticus. A. parasiticus produces aﬂatoxin B1 (AFB1), aﬂatoxin B2 (AFB2), aﬂatoxin G1 (AFG1) and
aﬂatoxin G2 (AFG2), whereas A. ﬂavus mainly produces AFB1 and AFB2. However, A. ﬂavus isolates
producing AFG1 and AFG2 also have been identiﬁed (Moore et al., 2017). When concentrations or MLs
mention ‘total’, it refers to the sum of these four aﬂatoxins and the structures are shown in Figure 1.
AFB1 is the most frequently found aﬂatoxin in contaminated samples and the three others are
generally not reported in the absence of AFB1 (FAO/WHO, 2017).
The aﬂatoxin-producing fungi are especially found in areas with hot, humid climate and aﬂatoxins are
found in food as a result of both pre- and post-harvest fungal contamination (EFSA, 2007a). The rate and
degree of contamination depend on temperature, humidity, soil and storage conditions. A. ﬂavus is
1 https://ec.europa.eu/food/sites/food/ﬁles/safety/docs/codex_cccf_11_agenda_item_08.pdf
2 https://ec.europa.eu/food/sites/food/ﬁles/safety/docs/codex_ccf_01_cl_2017-57_aflatoxins.pdf
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ubiquitous, favouring the aerial parts of the plants, e.g. leaves and ﬂowers, while A. parasiticus is more
adapted to a soil environment and is more limited distributed than A. ﬂavus (EFSA, 2007a).
Findings of aﬂatoxins have primarily been associated to imported foods such as peanuts, tree nuts,
dried fruit, spices, ﬁgs, crude vegetable oil, cocoa beans, maize and rice (EFSA, 2007a). However,
aﬂatoxins have in recent years also been found in cereals, especially maize grown in Kosovo, Serbia
and Italy (Battilani et al., 2016; Rapid Alert System for Food and Feed3).
Aﬂatoxins M1 (AFM1) and M2 (AFM2) are the hydroxylated metabolites of AFB1 and AFB2 and can
be found in milk or milk products obtained from livestock that have ingested contaminated feed.
Therefore, AFM1 and AFM2 were not considered in this opinion.
A wide spectrum of methods have been used for analysis of aﬂatoxins and the most widely applied
methods for quantitative analysis are high-performance liquid chromatography (HPLC) combined with
mass spectrometry (MS) or ﬂuorescence detection (FD) (EFSA, 2007a; FAO/WHO, 2017).
1.3.1. Previous assessments
Aﬂatoxins have previously been evaluated by EFSA’s CONTAM Panel in 2007 when EFSA was asked
to advice on the potential increase in risk to consumer health associated with a proposed change of
the existing EU ML in almonds, hazelnuts and pistachios (EFSA, 2007a). Aﬂatoxins were also evaluated
at several occasions by JECFA (i.e. at its 46th, 49th, 56th and 68th meetings, and last time at its 83rd
meeting in 2016 (FAO/WHO, 2017). The International Agency for Research on Cancer (IARC)
evaluated aﬂatoxins latest in 2012 (IARC, 2012).
Following absorption, aﬂatoxins undergo ﬁrst pass metabolism in the liver where they exert their
toxicity due to formation of toxic metabolites. The available toxicological knowledge on aﬂatoxins is
mostly related to AFB1. Aﬂatoxins are genotoxic and cause cancer in the liver, and it is therefore not
possible to identify an intake without risk. As only the carcinogenicity of aﬂatoxins is of concern in this
opinion, no further description of other toxic effects occurring at higher doses is given.
Figure 1: Chemical structures of aﬂatoxins B1, B2, G1 and G2
3 https://ec.europa.eu/food/safety/rasff_en; searched on 14 December 2017
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Carcinogenicity and mode of action
IARC (2012) classiﬁed aﬂatoxins as a group as carcinogenic to humans (Group 1) causing
hepatocellular carcinomas. In experimental animals, both AFB1 and AFG1 are carcinogenic, whereas
there is limited evidence for carcinogenicity of AFB2 and inadequate evidence for carcinogenicity of AFG2.
AFB1 and AFG1 are mutagenic in bacteria and AFB1 induces point mutations, mitotic recombination in
mammalian cells and genetic instability. There is strong evidence that the carcinogenicity is due to a
genotoxic mode of action (IARC, 2012). AFB1 is more potent than AFG1 both with respect to
mutagenicity and liver carcinogenicity (Wong and Hsieh, 1976), but AFG1 induced a higher incidence of
kidney tumours than AFB1 (EFSA, 2007a).
The double bond in the furan ring of AFB1 and AFG1 can be oxidised and form a reactive 8,9-exo-
epoxide that readily reacts with DNA and other nucleophiles (FAO/WHO, 2017). In DNA, the AFB1-N7-
guanine is formed resulting in persistent lesions, which may subsequently lead to transversion
mutations (IARC, 2012). Detoxication of AFB1 8,9-exo-epoxide can take place by several pathways
such as hydrolysis, and enzyme-mediated conjugations with glutathione, glucuronic acid and sulfate,
and excretion. In particular, glutathione conjugation of the reactive epoxide catalysed by glutathione
S-transferase (GST) isoforms in the liver appears to be critical and account for interspecies susceptibility
to AFB1 carcinogenicity. While mice with high a-class GST activity are relatively resistant, hepatic GST
activity is much less in rats, trout and humans and these species are therefore more susceptible.
Monkeys show intermediate activity (IARC, 2012; FAO/WHO, 2017). AFB1 is also directly detoxiﬁed by
oxidation. Due to human polymorphisms in cytochrome P450 enzymes responsible for detoxicating
AFB1 and inactivation of AFB1-8,9-exo-epoxide by GST isoforms, there is also some interindividual
variability in susceptibility to AFB1 among humans (EFSA, 2007a; IARC, 2012; FAO/WHO, 2017).
AFB1 dihydrodiol, a hydrolytic product of AFB1 8,9-epoxide, may bind to lysine residues of proteins
forming adducts, i.e. in serum albumin, which is used as a biomarker of aﬂatoxin exposure in many
studies (Guengerich et al., 2002; EFSA, 2007a; FAO/WHO, 2017).
Co-exposure to hepatitis viruses, in particular hepatitis B has a strong impact on the carcinogenic
risk to aﬂatoxins. In epidemiological studies, there is an interaction with hepatitis B infection, and
subjects positive for hepatitis B surface antigen (HBsAg) show at least a multiplicative risk when
present together with aﬂatoxin exposure (FAO/WHO, 2017). The interaction between aﬂatoxin and
hepatitis C remains to be resolved.
Dose–response considerations of carcinogenic risk
In its 49th meeting, JECFA (FAO/WHO, 1999) evaluated a large number of epidemiological studies
and identiﬁed the Chinese study on mortality from liver cancer by Yeh et al. (1989) as the pivotal
study. In this study, the mortality from liver cancer associated with exposure to aﬂatoxins both in
HBsAg+ and HBsAg– individuals were examined. JECFA estimated AFB1 potencies, which corresponded
to 0.3 cancers/year per 100,000 subjects per ng AFB1/kg body weight (bw) per day (uncertainty
range: 0.05–0.5) in HBsAg+ individuals and 0.01 cancers/year per 100,000 subjects per ng AFB1/kg
bw per day (uncertainty range: 0.002–0.03) in HBsAg individuals.
In 2007, EFSA’s CONTAM Panel also considered a large number of epidemiological studies on
aﬂatoxin exposure and hepatocellular carcinoma and identiﬁed the liver carcinogenicity of aﬂatoxins to
be the pivotal effect for the risk assessment (EFSA, 2007a). The Panel noted that the available
database from experimental animals and epidemiological studies were sufﬁcient for dose-response
modelling of AFB1. The CONTAM Panel considered many studies on aﬂatoxin and liver cancer in rats
and as a result used the 2 years carcinogenicity study in male Fisher rats given AFB1 by Wogan et al.
(1974) in its hazard characterisation. A benchmark dose lower conﬁdence limit for an extra cancer risk
of 10% (BMDL10) of 170 ng/kg bw per day was calculated. In its assessment of the cancer risk, the
CONTAM Panel conducted benchmark dose (BMD) analyses for the Chinese study on mortality from
liver cancer (Yeh et al., 1989) and for a group of studies from Africa on risk of liver cancer (Peers
et al., 1976 as corrected by Carlborg, 1979; Van Rensburg et al., 1985; Peers et al., 1987). The
prevalence of HBsAg+ was 23% in the Chinese cohort, between 21% and 28% for two studies from
Africa, and unknown for one study. The CONTAM Panel derived a BMDL10 on a background risk of
10.5% of 870 ng/kg bw per day from the study by Yeh et al. (1989), and a BMDL01 of 78 ng/kg bw
per day on a background risk of 0.17–0.50% was derived from the other studies. The CONTAM
Panel used these values for the risk characterisation. In addition, cancer rates for adults with a high
AFB1 intake were estimated based on cancer potency estimates made by JECFA as referenced above
for HBsAg– and HBsAg+ of populations with 0.2% and 7% prevalence of HBsAg+.
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At its 83rd meeting in 2016, JECFA reviewed and updated toxicological evidence on aﬂatoxin
hepatocarcinogenicity. JECFA re-conﬁrmed its previous conclusion that the lifetime dietary study in male
F344 rats (Wogan et al., 1974) is the most suitable study in experimental animals for modelling. Male
F344 rats appear to be particularly susceptible, and in this study, AFB1 as low as 1 lg/kg diet produced
liver tumours. Even lower levels of AFB1 in feed caused liver tumours in rainbow trout. Using a 4-week
exposure period with termination after 1 year showed a hepatotumourigenic response over a dose range
of 0.05–110 lg/kg diet in rainbow trout (Williams et al., 2009; Williams, 2012). JECFA (FAO/WHO, 2017)
noted that the dose-related tumourigenesis did not seem to deviate from a log-linear relationship and
that a similar relationship was observed between the dose of AFB1 and AFB1 – DNA adducts in trout and
rat liver (Bailey et al., 1998; Pottenger et al., 2014). These observations with doses approaching human
exposures lend support to the application of a linear non-threshold model in AFB1 cancer risk
assessment.
JECFA (FAO/WHO, 2017) concluded at its 83rd meeting that the prospective Chinese study by Yeh
et al. (1989), that demonstrated a close to linear relationship between aﬂatoxin exposure and
mortality from hepatocellular carcinoma, was still the pivotal study for the risk assessment. The risk
was recalculated using a Bayesian model averaging approach, as model uncertainty was a concern.
Using this technique, the posterior potency4 is estimated from observed data and prior weighing based
on the potential relationship between dose and the response at the low dose range, the posterior
weights were then calculated using the Akaike information criterion (AIC) representing each model ﬁt.
In line with the low-dose linear relationship observed for the animal data, JECFA gave higher weights
to the additive linear model of Wu-Williams et al. (1992) (40%) and the multistage model of Bowers
et al. (1993) (40%). The exponential multiplicative of Hoseyni (1992) and the multiplicative model of
Wu-Williams et al. (1992) received a lower weight (10% each). The posterior weights were 47%, 14%,
30% and 9%, respectively. Using model averaging, potency estimates of 0.017 (mean) and 0.049 (95%
upper bound (UB)) per 105 person years per ng/kg bw were calculated for HBsAg– individuals. And
potency estimates of 0.269 (mean) and 0.562 (95% UB) per 105 person years per ng/kg bw were
calculated for HBsAg+ individuals (FAO/WHO, 2017).
JECFA also modelled the rat studies of Wogan et al. (1974) using model averaging of several
models down to a risk of 0.001 and used this value to linearly extrapolate further down to a risk of
1 ng/kg bw per day in rats. This risk value for rats was extrapolated to a unit risk for humans using a
conversion factor of body weight 0.75, which resulted in a risk of 4.6 (95% conﬁdence interval (CI):
1.3, 74.9) per 105 person years per ng/kg bw (FAO/WHO, 2017).
Exposure assessments
In 2007, the CONTAM Panel assessed the average dietary exposure to AFT truncating the
occurrence data to the current EU MLs and using GEMS/Food Consumption Cluster diets data and data
from individual surveys (EFSA, 2007a). This assessment included exposure from almonds, hazelnuts,
pistachios, other nuts, maize, oilseeds, dried fruits and spices. For adults, this exposure ranged from
0.35 to 1.93 ng/kg bw per day (minimum lower bound (LB)–maximum UB) and for children from 0.56
to 1.91 ng/kg bw per day (minimum LB–maximum UB). Since 2007, no updated assessment of the
total dietary exposure to AFT has been carried out at the level of the European Union.
In 2016, JECFA calculated international estimates of chronic dietary exposure using the food
consumption data from the GEMS/Food cluster diets and a standard body weight of 60 kg (FAO/WHO,
2017). The calculations covered the exposure from cereals and pseudocereals, tree nuts and groundnuts,
spices, ﬁgs and soy (Lipp, 2018). The mean UB dietary AFT exposure ranged from 1.3 ng/kg bw per day
(cluster G08, including Austria, Germany, Poland and Spain) to 34.8 ng/kg bw per day (cluster G13,
including African countries and Haiti). JECFA reported that a similar pattern of exposure was observed
under the LB scenario. The dietary exposure for a high consumer was considered to be twice the mean
dietary exposure. Wheat was the main contributor to the UB dietary AFT exposure (range 37–76.5%) for
several countries, including many European countries. However, for cluster G10 (including European
countries such as Italy, Bulgaria, Estonia, Latvia and Lithuania), rice was the main contributor to the UB
dietary AFT exposure (range 34.5–80.3%). No information was provided regarding the major
contributors to the LB dietary AFT exposure. Based on these calculations and on national estimates,
JECFA concluded that with the exception of very high estimates of dietary exposure to AFT for some
4 Posterior estimates are obtained from the posterior distribution of the parameter of interest (potency), which is deﬁned as the
probability distribution from an unknown parameter considered as a random variable, and it is determined by the prior knowledge
about the parameter and the evidence gathered in the collected data about the parameter of interest (Congdon, 2006).
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African countries (105–850 ng/kg bw), all mean dietary AFT exposure was in the range < 0.01–58 ng/kg
bw per day with high consumer estimates in the range < 0.01–200 ng/kg bw per day. Considering the
different foods included in the exposure assessment, a direct comparison with the results generated by
the CONTAM Panel in 2007 is difﬁcult.
JECFA also performed an impact assessment of the implementation of different MLs in ready-to-eat
peanuts. The application of an ML of 15 lg/kg for ready-to-eat peanuts reduced the chronic UB dietary
exposure to AFT by a maximum of 20%. A further reduction of the ML to 4 lg/kg resulted in a
negligible additional reduction in dietary exposure. Based on this assessment, JECFA concluded that
‘enforcing an ML of 10, 8 or 4 lg/kg for ready-to-eat peanuts would have little further impact on
dietary exposure to AFT for the general population, compared with setting an ML of 15 lg/kg’ (FAO/
WHO, 2017).
Risk characterisation
In 2007, the CONTAM Panel calculated margins of exposure (MOEs) based on both BMDL10 and
BMDL01 values derived from the epidemiological data and the BMDL10 value derived from the animal
data. When evaluating AFT, the CONTAM Panel took into account that AFG1 and AFB2 were also
shown to be carcinogenic in rodents and assumed that the carcinogenic potency of AFT would be
similar to that of AFB1. The Panel (EFSA, 2007a) considered this to be a conservative approach. The
MOEs based on the BMDL10 from the animal data were considered to indicate a potential concern for
human health. The BMDLs from the epidemiological studies on populations with a high rate of HBsAg+
indicated a sensitivity similar to that of the sensitive rats. However, other subgroups were considered
likely to be less sensitive. The CONTAM Panel concluded that changing the ML for AFT from 4 to 8 or
10 lg/kg in almonds, hazelnuts and pistachios would have minor effects on estimates of dietary
exposures, calculated MOEs and cancer risk.
JECFA calculated at its 83rd meeting the cancer risk associated with estimated aﬂatoxin exposure in
different regions and concluded that the lowest cancer risks were estimated for clusters G07 and G08,
which include European and other developed countries. The cancer risk estimates for these clusters
ranged from < 0.01 to 0.1 aﬂatoxin-induced cancers per year and per 100,000 subjects. The highest
cancer risk was estimated for cluster G13 (sub-Saharan African countries and Haiti) and ranged from
0.21 to 3.94 aﬂatoxin-induced cancers per year and per 100,000 subjects (FAO/WHO, 2017).
1.3.2. Legislation
In this opinion, where reference is made to Regulations, the reference should be understood as
relating to the most recent amendment, unless otherwise stated.
In order to protect public health, Article 2 of Council Regulation (EEC) No 315/935 of 8 February
1993 laying down Community procedures for contaminants in food stipulates that, where necessary,
maximum tolerances for speciﬁc contaminants shall be established. Subsequently, a number of MLs for
aﬂatoxins and other mycotoxins in various foodstuffs were laid down in the Annex, Section 2 of
Commission Regulation (EC) No. 1881/20066 of 19 December 2006 setting MLs for certain contaminants
in foodstuffs. The MLs for aﬂatoxins are set following the principle of ‘as low as reasonably achievable’
(ALARA), derived from the frequency distribution of the respective food classes (usually at the 90–95th
percentile), taking into account the outcome of the risk assessment and the analytical capabilities.
The currently applicable MLs for aﬂatoxins in peanuts are shown in Table 1. The MLs refer to the
edible part of peanuts. If peanuts ‘in shell’ are analysed, it is assumed when calculating the aﬂatoxin
content all the contamination is on the edible part.
5 OJ L 37, 13.2.1993, p. 1–3.
6 OJ L 364, 20.12.2006, p. 5–24.
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According to Article 1 of Commission Regulation (EC) No 1881/2006, foodstuffs shall not be placed
on the market where they contain aﬂatoxins at a level exceeding the MLs. Article 3 of the Regulation
stipulates that foodstuffs not complying with the MLs shall not be used as food ingredients and/or shall
not be mixed with foodstuffs complying with the MLs.
Foodstuffs to be subjected to sorting or other physical treatment to reduce aﬂatoxin levels shall not
be mixed with foodstuffs intended for direct human consumption or with foodstuffs intended for use as
a food ingredient. Moreover, foodstuffs containing aﬂatoxins shall not be deliberately detoxiﬁed by
chemical treatments.
The following speciﬁc provisions for peanuts are laid down in Articles 4 and 5 of Commission
Regulation (EC) No 1881/2006. According to Article 4, peanuts and processed products thereof,
intended for direct human consumption or use as an ingredient in foodstuffs not complying with the
respective MLs can be placed on the market provided that these foodstuffs:
• are not intended for direct human consumption or use as an ingredient in foodstuffs;
• comply with the MLs for peanuts, to be subjected to sorting, or other physical treatment,
before human consumption or use as an ingredient in foodstuffs;
• are subjected to a treatment involving sorting or other physical treatment and that after this
treatment the MLs for peanuts and processed products thereof, intended for direct human
consumption or use as an ingredient in foodstuffs are not exceeded, and this treatment does not
result in other harmful residues are labelled clearly showing their use, and bearing the indication
‘product shall be subjected to sorting or other physical treatment to reduce aﬂatoxin
contamination before human consumption or use as an ingredient in foodstuffs’. The indication
shall be included on the label of each individual bag, box, etc., and on the original accompanying
document. The consignment/batch identiﬁcation code shall be indelibly marked on each
individual bag, box, etc., of the consignment and on the original accompanying document.
Article 5 of Commission Regulation (EC) No 1881/2006 states that in the absence of a clear
indication that their intended use is not for human consumption, the MLs for peanuts and processed
products thereof, intended for direct human consumption or use as an ingredient in foodstuffs shall
apply to all peanuts and derived products thereof placed on the market.
As regards the exception of peanuts for crushing and the application of the respective MLs, the
exception only applies to consignments which are clearly labelled showing their use and bearing the
indication ‘product to be subject to crushing for the production of reﬁned vegetable oil’.
Speciﬁc criteria for sampling and analysis of aﬂatoxins in peanuts are speciﬁed in Commission
Regulation (EC) No 401/20067 of 23 February 2006 laying down the methods of sampling and analysis
for the ofﬁcial control of the levels of mycotoxins in foodstuffs. The Regulation speciﬁes inter alia the
number and weight of samples to be collected in dependence on the size of the lot and the place of
sampling. A lot or sublot is only accepted if the laboratory sample is conform to the MLs, taking into
account the correction for recovery and measurement uncertainty. On the other hand, a commodity is
rejected if the laboratory sample exceeds the ML beyond reasonable doubt taking into account the
correction for recovery and measurement uncertainty.
Further requirements are laid down in this Regulation for sample preparation, including treatment of
the samples in the laboratory, calculation of proportion of shell/kernel of whole nuts and preparation of
Table 1: EU maximum levels for aﬂatoxins (lg/kg) in peanuts
Foodstuff
Aﬂatoxin
B1
Sum of aﬂatoxins
B1, B2, G1 and G2
Peanuts, to be subjected to sorting, or other physical treatment, before
human consumption or use as an ingredient in foodstuffs, with the
exception of:
• peanuts for crushing for reﬁned vegetable oil production
8.0 15.0
Peanuts and processed products thereof, intended for direct human
consumption or use as an ingredient in foodstuffs, with the exception of:
• crude vegetable oils destined for reﬁning
• reﬁned vegetable oils
2.0 4.0
7 OJ L 70, 9.3.2006, p. 12–34.
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replicate samples for enforcement, trade (defence) and reference (referee) purposes. Finally, Regulation
(EC) 401/2006 deﬁnes the analytical criteria, such as recovery, repeatability and reproducibility, which a
method has to fulﬁl for the ofﬁcial control on the levels of aﬂatoxins in foodstuffs.
Commission Regulation (EC) No 669/20098 lays down rules concerning the increased level of ofﬁcial
controls to be carried out at the point of entry on imports of speciﬁc feed and food commodities of non-
animal origin. It provides inter alia that the competent authorities at the designated point of entry shall
carry out with undue delay documentary checks, identity and physical checks, including laboratory
analysis at an increased frequency rate of 50% for peanuts in shell, peanuts shelled, peanut butter and
peanuts otherwise prepared or preserved from Bolivia, Gambia, Madagascar, Senegal and Sudan. A
release for free circulation within the EU is subject to favourable results from the required checks.
Commission Implementing Regulation (EU) No 884/20149 imposes special conditions governing the
import of feed and food from various third countries due to contamination risk by aﬂatoxins. The
Regulation applies inter alia to the import of peanuts in shell and shelled, peanut butter and peanuts
otherwise prepared or preserved (food and feed) originating in or consigned from China, Egypt, Ghana,
India, Brazil and Argentina. Each consignment must be accompanied by a speciﬁc health certiﬁcate, and
the results of sampling and analysis performed by the competent authorities of the country of origin, or
of the country where the consignment is consigned from if that country is different from the country of
origin, to ascertain compliance with Union legislation on MLs of aﬂatoxins. The competent authorities at
the designated points of import must carry out an identity check and a physical check by taking a sample
for analysis of AFB1 for feed or AFB1 and AFT contamination for food on the above-mentioned
consignments from Argentina at a frequency of 5%, from India and Brazil at a frequency of 10%, from
China and Egypt at a frequency of 20%, and from Ghana at a frequency of 50%.
Codex Alimentarius10 has set an ML of 15 lg/kg for aﬂatoxins in peanuts intended for further
processing. The ML is accompanied by requirements for sampling depending on the size of the lot, and
performance criteria for the analytical determination which are quite similar to the European
Regulation. In contrast, the Codex Standard does not stipulate an ML for peanuts and processed
products thereof, intended for direct human consumption or use as an ingredient in foodstuffs.
2. Data and methodologies
2.1. Hazard identiﬁcation and characterisation, and supporting
information for the assessment
2.1.1. Collection, selection of evidence
Given the short deadline of this request, previous assessments relevant for the current risk
assessment were used i.e. FAO/WHO (1999, 2008, 2017) and EFSA (2007a, 2009). No additional
search for scientiﬁc literature was conducted.
2.1.2. Appraisal of evidence
The information retrieved was screened and evaluated by relevant domain experts from the
CONTAM working group (WG) on ML of aﬂatoxins in peanuts and was used for the present assessment.
2.2. Occurrence data submitted to EFSA
2.2.1. Data collection and validation
For this statement, EFSA relied on occurrence data on aﬂatoxins in peanuts, peanut butter and
peanut oil available in the EFSA Chemical Occurrence database. These data were collected through the
continuous call for data which includes aﬂatoxins. Only samples in which AFB1, AFB2, AFG1 and AFG2
were analysed, were used in the present assessment.
8 Commission Regulation (EC) No 669/2009 of 24 July 2009 implementing Regulation (EC) No 882/2004 of the European
Parliament and of the Council as regards the increased level of ofﬁcial controls on imports of certain feed and food of non-
animal origin and amending Decision 2006/504/EC. OJ L 194, 25.7.2009, p. 11–21.
9 Commission Implementing Regulation (EU) No 884/2014 of 13 August 2014 imposing special conditions governing the import
of certain feed and food from certain third countries due to contamination risk by aﬂatoxins and repealing Regulation (EC)
No 1152/2009. OJ L 242, 14.8.2014, p. 4–19.
10 Codex Alimentarius: General Standard for Contaminants and Toxins in Food and Feed (CXS 193-1995, last amended in 2017).
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The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of
food consumption and occurrence data’.
All data on aﬂatoxins in peanut, peanuts butter and peanut oil available in the EFSA database by
29 September 2017 were extracted and further considered. Data received after this date were not
included.
2.2.2. Data analysis
A detailed quality control of the occurrence data was performed in order to identify duplicates, to
identify potential errors in the coding of the different samples under FoodEx classiﬁcation and to ensure
the overall comparability of the data. Upon identiﬁcation of potential inconsistencies, data providers were
contacted to provide further clariﬁcation. The outcome of the data analysis is shown in Section 3.2.1.
For analytical results of the four individual aﬂatoxins, the left-censored data (analytical data below the
limit of detection (LOD)/limit of quantiﬁcation (LOQ)) were treated by the substitution method as
recommended in the ‘Principles and Methods for the Risk Assessment of Chemicals in Food’ (WHO/IPCS,
2009). The same method is described in the EFSA scientiﬁc report ‘Management of left-censored data in
dietary exposure assessment of chemical substances’ (EFSA, 2010b), as an option in the treatment of
left-censored data. The guidance suggests that the LB and UB approach should be used for chemicals
likely to be present in the food (e.g. naturally occurring contaminants, nutrients and mycotoxins). At the
LB, results below the LOQ or LOD were replaced by zero; at the UB, the results below the LOD were
replaced by the numerical value of the LOD and those below the LOQ were replaced by the numerical
value of the LOQ. Additionally, a middle bound (MB) approach was used by assigning a value of LOD/2 or
LOQ/2 to the left-censored data.
In addition, occurrence values for AFT were calculated from the analytical results of the individual
aﬂatoxins. Considering that AFB1 is the aﬂatoxin that is most frequently found and at the highest
concentration, and that not all aﬂatoxin producing moulds produce all four aﬂatoxins, simply adding
the four LOQ values for samples in which none of the aﬂatoxins are quantiﬁed, would overestimate the
UB AFT level. Therefore, the concentration of AFT was calculated for each sample following the
principles listed below:
• when quantiﬁed results were available for all four aﬂatoxins, the concentration of AFT was
calculated as the sum of all concentrations;
• when the results for all four aﬂatoxins were left-censored, the UB concentration of AFT was
calculated as twice the LOD/LOQ for AFB1 (the main contributor) unless the sum of the four
LOD/LOQ was lower;
• when there were both, quantiﬁed and left-censored results, the UB concentration of AFT was
calculated as the sum of quantiﬁed values and twice the LOD/LOQ for AFB1, unless the sum of
the quantiﬁed values and the LOD/LOQ of the unquantiﬁed aﬂatoxins was lower.
2.3. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database) provides
a compilation of existing national information on food consumption at individual level. It was ﬁrst built in
2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the Comprehensive
Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest version of the
Comprehensive Database11 was used with subjects classiﬁed in different age classes as follows:
• Infants: < 12 months old
• Toddlers: ≥ 12 months to < 36 months old
• Other children: ≥ 36 months to < 10 years old
• Adolescents: ≥ 10 years to < 18 years old
• Adults: ≥ 18 years to < 65 years old
• Elderly: ≥ 65 years to < 75 years old
• Very elderly: ≥ 75 years old.
11 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb
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Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’
(≥ 15 years to ≤ 45 years old; Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old; Greece).
Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering from 3 to 7 days per subject. As a
result of the differences in the methods used for data collection, direct country-to-country comparisons
can be misleading.
2.4. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food groups (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800 items
(food names or generic food names) at the fourth level.
2.5. Methodology to assess the inﬂuence of increasing the maximum
level on the mean concentration of ‘aﬂatoxin total’
No data were available regarding consignments that were not shipped to the EU due to levels
exceeding the current ML of 4 lg/kg but would have been placed on the EU market if a higher ML was
in place. Therefore, the impact of increasing the ML from 4 to 10 lg/kg on the mean concentration of
AFT in peanuts was assessed using a simulation approach by bootstrapping. New data sets, of equal
size to the observed data set, were generated by selecting (with replacement) samples from the
observed data set under the constraint that the proportion of non-compliant samples would remain
the same after the increase of the ML. It should be noted that in the context of this Scientiﬁc Opinion,
the measurement uncertainty was not taken into account to decide whether a sample is
non-compliant. This approach was implemented in the SAS software (version 9.4) as follows:
• n concentration values were randomly drawn with replacement, where n is the total number of
concentration values available in the initial data set, as follows
– n p values were drawn from the observed values between 10 lg/kg and the maximum
AFT concentration, where p is the proportion of non-compliance in the initial data set,
– n p p’/(1  p’) values were drawn from the observed values between 4 and 10 lg/kg,
where p’ is the proportion of samples between 4 and 10 lg/kg among the total number
samples above 4 lg/kg estimated from the initial data set,
– n–n p–n p p’/(1  p’) values were drawn from the observed values below 4 lg/kg.
• The LB/MB/UB mean AFT concentration was estimated from the simulated data set and divided
by the LB/MB/UB mean AFT concentration estimated from the initial data set to calculate the
increase factor.
• This procedure was repeated 1,000 times and the mean increase factor was calculated with its
95% CI. In a sensitivity analysis, the number of iterations was increased by a factor of 10–
10,000, demonstrating that 1,000 iterations were sufﬁcient to fully reﬂect the variability of the
reported data set.
2.6. Exposure assessment
The CONTAM Panel considered that only chronic dietary exposure had to be assessed. As
suggested by the EFSA WG on Food Consumption and Exposure (EFSA, 2011a), dietary surveys with
only 1 day per subject were excluded from the current assessment because they are not adequate to
assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary studies, when
the protocol prescribed more reporting days per individual, were also excluded from the chronic
exposure assessment. When, for one particular country and age class, two different dietary surveys
were available only the most recent one was used.
For calculating the chronic dietary exposure, food consumption and body weight data at the individual
level were accessed in the Comprehensive Database. Occurrence data and consumption data for peanuts
and relevant processed products were matched to one another. For each individual of the selected
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surveys, the average daily consumption of the different food items were combined with the mean
occurrence values of the corresponding food samples collected (pooled European occurrence data), and
the resulting exposures per food were summed in order to obtain the total chronic exposure at individual
level (standardised by using the individual body weight). The mean of the individual exposures were
subsequently calculated for each dietary survey and age class having at least ﬁve consumers. The 95th
percentile exposure was calculated for survey and age class combinations with 61 or more consumers.
Before matching the consumption data to the corresponding occurrence data, foods that may
contain peanuts were identiﬁed. Based on the available data for corresponding recipes and/or
commercial products, those foods were assigned a given content of peanuts, together with a
probability for that food to actually contain peanuts. A number of consumption events was selected at
random for each of these foods (proportional to the above mentioned probability) and converted to
the corresponding amount of peanut or its primary derivative.
2.7. Risk characterisation
The CONTAM Panel applied the general principles of the risk characterisation process for chemicals
in food as described by WHO/IPCS (2009) and the relevant EFSA guidance documents (see
Appendix A).
3. Assessment
3.1. Hazard identiﬁcation and characterisation
Given the short deadline of the current request, no toxicological evaluation was performed by the
CONTAM Panel. Instead, the Panel decided to base the assessment on the recent JECFA evaluation
and used the study by Yeh et al. (1989) for the risk characterisation (FAO/WHO, 2017).
The CONTAM Panel considered the possibility to apply an MOE approach based on a BMDL value
calculated from the models used by JECFA to calculate the cancer potency from the study by Yeh et al.
(1989)Yeh et al. (FAO/WHO, 2017; see Section 1.3.1 for further details). In contrast to the evaluation
in 2007 (see Section 1.3.1), the CONTAM Panel took the HBsAg status into account in the BMD
analyses and used model averaging (EFSA Scientiﬁc Committee, 2017). However, the BMD analysis
showed that based on the dose ranges studied, a very small trend in the dose–response curve was
observed for HBsAg- subjects (see Appendix B) which results in wide BMD conﬁdence intervals.
Therefore, BMD conﬁdence interval calculation was not appropriate and the CONTAM Panel decided to
use the cancer potency estimates reported by JECFA (FAO/WHO, 2017) in the present assessment.
3.2. Occurrence data
3.2.1. Occurrence data on food submitted to EFSA
The data for the present assessment were provided by national authorities from Austria, Belgium,
Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland,
Latvia, Luxembourg, the Netherlands, Poland, Portugal, Slovakia, Slovenia and Spain (Figure 2).
An initial number of 36,667 analytical results on aﬂatoxins in food were available in the EFSA
database for AFB1, AFB2, AFG1 or AFG2 in peanuts, peanut butter and peanut oil collected throughout
the years 2007–2017 (Figure 3).
These data were subject to the validation processes described in Section 2.2.1 and data providers
were invited to clarify possible inconsistencies identiﬁed by EFSA’s DATA Unit.
Furthermore, the overall data set was carefully analysed before being used to estimate dietary
exposure and a total of 2,393 records were excluded from the ﬁnal data set. Criteria for exclusion of
these analytical results are also detailed in Annex A, Table A.1.
The data set was also analysed for possible correlations between mean concentration, sampling
year and sampling strategy. As no speciﬁc correlations could be identiﬁed, the CONTAM Panel decided
not to exclude any samples on the basis of the sampling strategy or sampling year.
In total, 34,324 analytical results for AFB1, AFB2, AFG1 and AFG2 were taken into account, which
corresponds to 8,581 samples. Samples were taken in 20 Member States (Figure 2) throughout the
years 2007–2017 (Figure 3).
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Detailed summary statistics on the occurrence data are presented in Annex A, Table A.2. Most of
the data as collected had AFT concentrations less than 10 lg/kg. The highest value in peanuts was
1,429 lg/kg and the highest value for peanut butter was 406 lg/kg. All results in peanut oil (n = 14)
were left-censored. The occurrence data for AFB1 and AFT in peanuts and peanut butter are
summarised in Table 2.
Figure 2: Number of samples reported by Member States
Figure 3: Number of samples submitted by year
Table 2: Summary statistics of aﬂatoxin B1 and ‘aﬂatoxin total’ concentrations (lg/kg) in peanut
and peanut butter
Food group N Substance LC (%) Percentile
Concentration (lg/kg)
LB MB UB
Peanut 8,095 AFB1 87.2 Mean 2.03 2.23 2.43
P50 0 0.10 0.20
P95 4.40 4.40 4.40
AFT 86.6 Mean 2.65 3.11 3.56
P50 0 0.30 0.50
P95 5.20 5.80 6.40
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Figure 4 shows the percentage of samples for peanuts and peanut butter for different
concentration ranges, which were deﬁned by the current and suggested ML. From the 8,095 peanut
samples for which the concentration of AFT was calculated, 87% of the samples had a AFT
concentration below the LOD/LOQ, 6% of the samples had a concentration of 4 lg/kg or less, 3% had
a concentration between 4 and 10 lg/kg and 4% of the samples had a concentration exceeding the
suggested ML of 10 lg/kg. For peanut butter, the percentage of quantiﬁed results was higher, but the
fractions exceeding either 4 or 10 lg/kg were lower.
The relative contribution of AFB1 to the AFT concentration was calculated for all samples of peanut
and peanut butter where measurable amounts of AFB1 were reported (see Table 3). On average, AFB1
contributed for more than 60% to the MB concentration of AFT. It was noted that the contribution of AFB1
to AFT increased with increasing concentration of AFB1. Hence, if the ML of AFTwould increase from 4 to
10 lg/kg, this would also have an impact on the number of samples exceeding the current ML of AFB1.
Food group N Substance LC (%) Percentile
Concentration (lg/kg)
LB MB UB
Peanut butter 472 AFB1 64.2 Mean 1.07 1.16 1.25
P50 0 0.10 0.20
P95 2.70 2.70 2.70
AFT 63.8 Mean 1.47 1.69 1.92
P50 0 0.20 0.40
P95 3.50 3.70 3.90
AFB1: aﬂatoxin B1; AFT: ‘aﬂatoxin total’; LB: lower bound; LC: left-censored; MB: middle bound; P50: 50th percentile; P95: 95th
percentile; UB: upper bound.
LOD: limit of detection; LOQ: limit of quantiﬁcation.
Figure 4: Comparison of ‘aﬂatoxin total’ concentrations with current and proposed maximum level for
peanuts and peanut butter
Table 3: Contribution of aﬂatoxin B1 to the ‘aﬂatoxin total’ middle bound concentration in all samples
of peanut and peanut butter where measurable amounts of aﬂatoxin B1 were reported
Food group Concentration AFB1 N Mean
Percentile
5th 25th 50th 75th 95th
Peanut 1 lg/kg or less 252 61.2 23.2 50.0 66.7 76.9 85.2
1–10 lg/kg 521 71.7 34.6 63.0 75.9 84.2 91.3
10 lg/kg or more 260 78.4 34.0 77.9 83.6 87.8 92.9
Peanut butter 1 lg/kg or less 114 66.5 45.7 60.0 66.7 74.7 85.2
1–10 lg/kg 53 66.0 n/a(a) 53.8 67.3 75.5 n/a
10 lg/kg or more 2 75.3 n/a n/a 75.3 n/a n/a
AFB1: aﬂatoxin B1; N: Number of Samples; n/a: not available.
(a): Too limited number of samples to calculate percentile.
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Available occurrence data were mostly generated with HPLC combined with FD (53%), MS (30%)
or tandem mass spectrometry (MS/MS, 3%), which are generally capable of quantifying AFB1, AFB2,
AFG1 and AFG2 at the concentrations of interest. For 14% of the samples, a detailed analytical
method was not reported by the data provider but, based on the analytical methods reported by the
same data providers over the different years, these samples were most likely analysed using HPLC-FD.
The reported LOQs for peanut and peanut butter are plotted in Figure 5.
3.2.2. Food processing
Processes applied on foods such as heating, roasting and baking can reduce the levels of aﬂatoxins
but do not completely eliminate the toxins, and the degree of elimination is variable and depends on
the process as well as the conditions under which the process is applied (FAO/WHO, 2017). Roasting
of peanuts reduces the aﬂatoxin level by 50–80% (FAO/WHO, 1999). During the processing of oil,
levels of aﬂatoxins also decrease. Studies have shown that crude peanut oil contains less aﬂatoxins
than the raw peanuts, while reﬁned oil contains only small amounts of aﬂatoxins (Parker and Melnick,
1966; Abalaka and Elegbede, 1982; Abalaka, 1984; Bordin et al., 2014). For example, Parker and
Melnick (1966) found that after processing a sample of peanuts to reﬁned oil, the amount of AFB1
decreased from 5,500 lg/kg in the peanuts to a concentration of less than 1 lg/kg in the oil.
3.3. Inﬂuence of increasing the maximum level
3.3.1. Inﬂuence on the mean aﬂatoxin level in peanuts and products derived
thereof
No data were available regarding consignments that were not shipped to the EU due to levels
exceeding the current ML of 4 lg/kg but would have been placed on the EU market if a higher ML was
in place. Therefore, the impact of increasing the ML from 4 to 10 lg/kg was assessed according to the
methodology described in Section 2.5. As all samples for peanut oil were left-censored and the number
of samples in peanut butter with concentrations above 10 lg/kg was too small for bootstrap analysis
(only four samples), this simulation was carried out for peanuts only. It should be noted that in the
context of this Scientiﬁc Opinion, the measurement uncertainty was not taken into account to decide
whether a sample is non-compliant.
The number of samples in the original and simulated data sets are depicted in Figure 6. The
highest AFT concentration observed in peanuts was 1,429 lg/kg.
Box-plot: whiskers at 5th percentile and 95th percentile, box at 25th percentile and 75th percentile with line at
50th percentile; N: number of samples.
Figure 5: Distribution of the reported limits of quantiﬁcation for ‘aﬂatoxin total’ in lg/kg
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As a result of this analysis, it was estimated that changing the ML for AFT from 4 to 10 lg/kg in
peanuts, would increase the LB, MB and UB mean AFT concentrations by factors of 1.75 (95%
CI = 1.51–2.03), 1.64 (95% CI = 1.44–1.88) and 1.56 (95% CI = 1.38–1.77), respectively.
3.3.2. Inﬂuence of increasing the maximum level on chronic dietary exposure
from peanuts and peanut butter
Due to time constraints, an assessment of the total dietary exposure to AFT (considering all food
sources) was not considered feasible. Furthermore, considering that extraction and reﬁning of oil may
reduce the concentrations of aﬂatoxins considerably, that the ML under assessment does not apply to
peanut oil and that available occurrence data for peanut oil were all left-censored, peanut oil was not
included in the exposure assessment.
Chronic dietary exposure to AFT in peanuts and peanut butter was hence estimated across Europe
using the methodology described in Section 2.6. A total of 35 dietary surveys, carried out in
19 different Member States, were selected for this assessment. These dietary surveys, the number of
subjects and the number of consumers available per age class are described in Annex A, Table A.3.
Prior to the identiﬁcation of the peanut and peanut butter consumers, eating occasions referring to
food items that may contain peanut or peanut butter were converted assuming the contents and
probabilities reported in Annex A, Table A.4. Consumers of peanuts and peanut butter represent only
on average 7% (range: 0–36%) of the total population (see Annex A, Table A.3); therefore, the
CONTAM Panel concluded that exposure estimates for consumers only were the most adequate.
The impact of increasing the ML on chronic dietary exposure was assessed by presenting two
different exposure scenarios:
• the ‘Current ML’ scenario represents exposure to the current market situation with an ML of
4 lg/kg, using the mean occurrence values for AFT in peanuts and peanut butter (see also
Table 2).
n = number of samples; p = probability of non-compliance with the maximum level; p’ = probability of a
concentration between 4 and 10 lg/kg when non-compliant with the current maximum level.
Figure 6: Illustration of the methodology to simulate the data set on the occurrence of aﬂatoxins
after the increase of the maximum level
Maximum level of ‘aﬂatoxin total’ in peanuts and processed products thereof
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2018;16(2):5175
• the ‘Increased ML’ scenario represents exposure to a simulated market situation with an ML of
10 lg/kg. In this scenario, the mean occurrence values for AFT in both peanuts and peanut
butter were multiplied with the increase factors reported for peanuts in Section 3.3.1. In the
absence of a speciﬁc increase factor for peanut butter, it was assumed that the increase of
aﬂatoxin levels in peanut butter would be proportional to the increase anticipated for peanuts.
Table 4 summarises the mean chronic dietary exposure estimates across surveys for both exposure
scenarios. Detailed summary statistics on the exposure estimates calculated for each dietary survey
are presented in Annex A, Table A.5. While 95th percentile estimates require a minimum of
61 observations to be considered as statistically robust, mean estimates would normally require a
minimum of ﬁve observations (EFSA, 2011a). Survey and age class combinations having less than ﬁve
consumers of peanuts or peanut products are therefore not presented.
The highest mean chronic exposures (for consumers only) were calculated for adolescents and other
children. Among the highest UB exposures for adolescents, the ‘Current ML’ scenario amounted to
2.74 ng/kg bw per day, whereas the ‘Increased ML’ scenario amounted to 4.28 ng/kg bw per day. Due
to the smaller contribution of left-censored data, the difference between LB and UB estimates was found
to be smaller for the ‘Increased ML’ scenario (15–20%) compared to the ‘Current ML’ scenario (30–35%).
Regarding the highly exposed consumers within a given dietary survey and age class, only few
surveys contained sufﬁcient consumers to derive a reliable 95th percentile exposure. For adults, the
only age class where a sufﬁcient number of 95th percentiles could be derived, exposure of high
consumers was found to be two to four times higher compared to the exposure of average consumers,
but it is not clear whether this ratio is also applicable to the most exposed age classes such as
adolescents and other children. The CONTAM Panel therefore concluded that a reliable exposure
assessment for high consumers cannot be carried out, taking note of the uncertainty.
3.4. Risk characterisation
Considering that AFB1 is the major contributor to the exposure to AFT and that AFB1 is the most
potent aﬂatoxin, the CONTAM Panel used a conservative approach and used the cancer potency
Table 4: Mean chronic dietary exposure to ‘aﬂatoxin total’ from peanuts, peanut butter and
processed products thereof (consumers only) expressed in ng/kg bw per day across
European dietary surveys, assuming two different scenarios
Age class(a) Scenario N
Mean dietary exposure (ng/kg bw per day)(b)
Minimum(c) Median(c) Maximum(c)
LB UB LB UB LB UB
Infants Current ML 2 0.04 0.05 0.16 0.21 0.27 0.36
Increased ML 2 0.07 0.08 0.28 0.32 0.48 0.56
Toddlers Current ML 5 0.39 0.51 0.70 0.94 1.27 1.66
Increased ML 5 0.68 0.80 1.22 1.46 2.22 2.59
Other children Current ML 16 0.30 0.40 0.81 1.07 1.69 2.27
Increased ML 16 0.53 0.63 1.42 1.67 2.95 3.53
Adolescents Current ML 14 0.13 0.18 0.52 0.69 2.06 2.74
Increased ML 14 0.23 0.28 0.91 1.07 3.61 4.28
Adults Current ML 17 0.16 0.21 0.50 0.67 1.25 1.68
Increased ML 17 0.28 0.33 0.88 1.05 2.19 2.63
Elderly Current ML 12 0.07 0.10 0.34 0.46 0.74 0.99
Increased ML 12 0.13 0.15 0.60 0.71 1.29 1.54
Very elderly Current ML 4 0.21 0.28 0.36 0.47 0.73 0.97
Increased ML 4 0.37 0.44 0.62 0.74 1.27 1.52
bw: body weight; LB: lower bound; ML: maximum level; N: number of surveys; UB: upper bound.
(a): Section 2.4 describes the age range within each age class.
(b): The mean estimates obtained on dietary surveys/age classes with less than ﬁve observations (consumers) may not be
statistically robust (EFSA, 2011a). Those estimates were not included in this table.
(c): Estimates were rounded to two decimal places.
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estimates calculated for AFB1 for the risk characterisation of AFT. It should be noted that the exposure
estimates calculated in this Scientiﬁc Opinion refer to consumers of peanuts and peanut butter only.
Consumers of peanuts and peanut butter represent on average 7% (range: 0–36%) of the total
population (see Section 3.3.2).
Using model averaging, JECFA calculated potency estimates of 0.017 (mean) and 0.049 (95% UB)
per 105 person years per ng/kg bw for HBsAg– individuals and 0.269 (mean) and 0.562 (95% UB) per
105 person years per ng/kg bw for HBsAg+ individuals12 (FAO/WHO, 2017; see Section 1.3.1 for
further details).
According to Schweitzer et al. (2015), the HBsAg seroprevalence ranges between 0.01% and
5.61% in EU Member States. The lowest seroprevalence of 0.01% was reported for the UK and the
highest for Romania. No data were presented for Estonia, Latvia, Luxembourg, Malta and Finland. The
overall prevalence is 2.06% for the European region.
Based on the mean potency estimates and a prevalence of HBsAg of 0.01%, the CONTAM
Panel estimated the cancer risk due to peanut and peanut butter consumption, under the scenario of the
current ML, to be between 0.001 and 0.047 aﬂatoxin-induced cancers per year per 100,000 persons,
across dietary surveys and age groups (Table 5). Under the scenario of the increased ML, it ranged
between 0.001 and 0.073 aﬂatoxin-induced cancers per year per 100,000 persons, across dietary
surveys and age groups. In adults, the estimated cancer risk ranged between 0.003 and 0.029 aﬂatoxin-
induced cancers per year per 100,000 adults under the scenario of the current ML. For the scenario of the
increased ML, the cancer risk is estimated to be between 0.005 and 0.045 aﬂatoxin-induced cancers per
year per 100,000 adults. The highest exposure and consequent cancer risk were calculated for
adolescents. For this age class, the cancer risk due to peanut and peanut butter consumption was
estimated to be between 0.002 and 0.047 aﬂatoxin-induced cancers per year per 100,000 adolescents
under the scenario of the current ML. For the scenario of the increased ML, the cancer risk is estimated to
be between 0.004 and 0.073 aﬂatoxin-induced cancers per year per 100,000 adolescents.
Table 5: Cancer risk calculated from the mean chronic dietary exposure to ‘aﬂatoxin total’(a), the
mean potency estimates of the cancer risk and a prevalence of HBsAg of 0.01%
Age class(b) Scenario N
Cancer risk (aﬂatoxin-induced cancers per year and per
100,000 subjects)
Minimum Median Maximum
LB UB LB UB LB UB
Infants Current ML 2 0.001 0.001 0.003 0.004 0.005 0.006
Increased ML 2 0.001 0.001 0.005 0.005 0.008 0.010
Toddlers Current ML 5 0.007 0.009 0.012 0.016 0.022 0.028
Increased ML 5 0.012 0.014 0.021 0.025 0.038 0.044
Other children Current ML 16 0.005 0.007 0.014 0.018 0.029 0.039
Increased ML 16 0.009 0.011 0.024 0.028 0.050 0.060
Adolescents Current ML 14 0.002 0.003 0.009 0.012 0.035 0.047
Increased ML 14 0.004 0.005 0.015 0.018 0.061 0.073
Adults Current ML 17 0.003 0.004 0.009 0.011 0.021 0.029
Increased ML 17 0.005 0.006 0.015 0.018 0.037 0.045
Elderly Current ML 12 0.001 0.002 0.006 0.008 0.013 0.017
Increased ML 12 0.002 0.003 0.010 0.012 0.022 0.026
Very elderly Current ML 4 0.004 0.005 0.006 0.008 0.012 0.017
Increased ML 4 0.006 0.008 0.011 0.012 0.022 0.026
LB: lower bound; ML: maximum level; N: number of surveys; UB: upper bound.
(a): Mean chronic dietary exposure to ‘aﬂatoxin total’ from peanuts, peanut butter and processed products thereof (consumers
only) calculated from mean LB and UB occurrence values for two different scenarios.
(b): Section 2.4 describes the age range within each age class.
12 These values can be interpreted as follows: when 100,000 HBsAg+ subjects are exposed for 1 year to 1 ng/kg bw per day, it
is estimated that this relates to 0.269 aﬂatoxin-induced cancer cases with an 95% UB of 0.562.
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Based on the UB potency estimates and a prevalence of HBsAg of 5.61%, the CONTAM
Panel estimated the cancer risk due to peanut and peanut butter consumption, under the scenario of the
current ML, to be between 0.003 and 0.213 aﬂatoxin-induced cancers per year per 100,000 persons,
across dietary surveys and age groups, (Table 6). Under the scenario of the increased ML, it ranged
between 0.006 and 0.333 aﬂatoxin-induced cancers per year per 100,000 persons, across dietary
surveys and age groups. In adults, the cancer risk ranged between 0.012 and 0.131 aﬂatoxin-induced
cancers per year per 100,000 adults under the scenario of the current ML. For the scenario of the
increased ML, the cancer risk is estimated to be between 0.022 and 0.204 aﬂatoxin-induced cancers per
year per 100,000 adults. For adolescents, the cancer risk due to peanut and peanut butter consumption
was estimated to be between 0.010 and 0.213 aﬂatoxin-induced cancers per year per 100,000
adolescents under the scenario of the current ML. For the scenario of the increased ML, the cancer risk is
estimated to be between 0.018 and 0.333 aﬂatoxin-induced cancers per year per 100,000 adolescents.
According to the WHO Guideline for drinking-water quality (WHO, 2011), an excess lifetime cancer
risk of 105 or less is considered to be of low risk for health concern.13 Assuming a lifetime expectancy
of 70 years, this corresponds to a yearly excess cancer risk of 0.014 additional cancer cases14 per
100,000 subjects. Comparing the estimated aﬂatoxin-induced cancers calculated under the current ML
scenario with this yearly excess cancer risk, a higher risk for consumers of peanut and peanut butter is
identiﬁed in some surveys. The calculated cancer risks indicate that an increase of the ML would
further increase the risk by a factor of 1.6–1.8.
3.5. Analysis of the divergent opinion with JECFA
As explained in Section 1.3.1, JECFA concluded in a similar assessment that ‘enforcing an ML of 10,
8 or 4 lg/kg for ready-to-eat peanuts would have little further impact on dietary exposure to AFT for
the general population, compared with setting an ML of 15 lg/kg’.
Table 6: Cancer risk calculated from the mean chronic dietary exposure to ‘aﬂatoxin total’(a), the
upper bound potency estimate of the cancer risk and a prevalence of HBsAg of 5.61%
Age class(b) Scenario N
Cancer risk (aﬂatoxin-induced cancers per year and per
100,000 subjects)
Minimum Median Maximum
LB UB LB UB LB UB
Infants Current ML 2 0.003 0.004 0.012 0.016 0.021 0.028
Increased ML 2 0.006 0.007 0.021 0.025 0.037 0.043
Toddlers Current ML 5 0.030 0.040 0.054 0.073 0.099 0.129
Increased ML 5 0.053 0.062 0.095 0.114 0.173 0.202
Other children Current ML 16 0.023 0.032 0.063 0.083 0.131 0.176
Increased ML 16 0.041 0.049 0.110 0.130 0.230 0.275
Adolescents Current ML 14 0.010 0.014 0.040 0.053 0.160 0.213
Increased ML 14 0.018 0.022 0.070 0.083 0.281 0.333
Adults Current ML 17 0.012 0.017 0.039 0.052 0.097 0.131
Increased ML 17 0.022 0.026 0.068 0.081 0.171 0.204
Elderly Current ML 12 0.006 0.008 0.027 0.035 0.057 0.077
Increased ML 12 0.010 0.012 0.046 0.055 0.100 0.120
Very elderly Current ML 4 0.017 0.022 0.028 0.037 0.057 0.076
Increased ML 4 0.029 0.034 0.048 0.057 0.099 0.118
LB: lower bound; ML: maximum level; N: number of surveys; UB: upper bound.
(a): Mean chronic dietary exposure to ‘aﬂatoxin total’ from peanuts, peanut butter and processed products thereof (consumers
only) calculated from mean LB and UB occurrence values for two different scenarios.
(b): Section 2.4 describes the age range within each age class.
13 An excess lifetime cancer risk of 105 is equivalent to one additional case of cancer per 100,000 of the population ingesting
drinking water containing the substance at the guideline value for 70 years (WHO, 2011). This risk level is used by the WHO
to set guidance values for chemicals in drinking water.
14 The yearly extra risk was calculated by dividing the excess lifetime cancer risk of 105 by the lifetime expectancy of 70 years
and expressing it per 100,000 subjects.
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This divergent opinion relates to methodological differences in the exposure assessment, namely
the treatment of samples exceeding the considered ML, the foods included in the exposure assessment
and the target population (consumers only vs general population).
The CONTAM Panel notes that the exposure to aﬂatoxins from peanuts and products derived thereof
comes in addition to dietary aﬂatoxin exposure from other sources. Due to the short deadline of this
mandate, an assessment of the total chronic dietary exposure to AFT (considering all food sources) was
not considered feasible, and the CONTAM Panel limited the exposure assessment to peanuts ready-to-
eat, peanut butter and processed products thereof. The exposure was calculated for consumers only,
since consumers of peanuts and peanut butter represent on average 7% (range: 0–36%) of the total
population. The CONTAM Panel consequently based its conclusion on the assessment of the risk for
consumers only, whereas JECFA based its conclusions on the risk for the general population. The
CONTAM Panel recommends performing a full risk assessment on aﬂatoxins that would allow the
interpretation of the exposure from peanuts in the perspective of the total dietary exposure to AFT.
JECFA and the CONTAM Panel also deviate in the treatment of samples exceeding the considered
ML. JECFA excluded all samples for which the concentration of AFT exceeded the considered ML (4, 8,
10 or 15 lg/kg). The CONTAM Panel and EFSA used this approach also in previous assessments (e.g.
EFSA, 2007a, 2012). A limitation of this approach is the assumption that all samples comply with the
ML that is in place. In practice, a certain percentage of samples on the market will exceed the ML, and
therefore, an underestimation of the risk is made. To improve and reﬁne risk assessment methods, the
methodology used by EFSA for dietary exposure assessment has been revised. In the opinion on MLs
of deoxynivalenol (DON) in certain cereal products (EFSA CONTAM Panel, 2013), another approach
was used to create a data set representing the occurrence of DON for a hypothetical ML. In this
approach, a new data set was simulated by bootstrapping, assuming that the proportion of non-
compliant samples observed in the initial data set will remain the same after increase of the ML and no
samples above the considered ML were excluded. The CONTAM Panel used a similar approach in the
present evaluation where, according to the occurrence data available in the EFSA database, 7% of the
samples on peanut exceed the EU ML of 4 lg/kg. Hence, the CONTAM Panel simulated a new data set
assuming that also 7% of the samples would be non-compliant under the increased ML.
3.6. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of effect on public health of a
possible increase of the ML for AFT from 4 to 10 lg/kg in peanuts and processed products thereof,
intended for direct human consumption or use as an ingredient in foodstuffs has been performed
following the guidance of the Opinion of the Scientiﬁc Committee related to Uncertainties in Dietary
Exposure Assessment (EFSA, 2007b). In addition, the report on ‘Characterizing and Communicating
Uncertainty in Exposure Assessment’ has been considered (WHO/IPCS, 2008). According to the
guidance provided by the EFSA opinion (2007b), the following sources of uncertainties have been
considered: assessment objectives, exposure scenario/exposure model and model input (parameters).
3.6.1. Assessment objectives
The objectives of the assessment are clearly speciﬁed in the terms of reference. The assessment is
only focused on the free parent aﬂatoxins and because of lack of data does not take into account
potentially modiﬁed aﬂatoxins. A re-evaluation of the toxicological properties of aﬂatoxins is beyond
the scope of this assessment.
3.6.2. Exposure scenario/exposure model
The occurrence data used in the exposure assessment were mainly the results of monitoring
programmes. Due to the sampling strategy (selective/targeted sampling design) and to the
performance of the analytical methods which aimed to verify compliance with MLs but not to
determine background levels, the data are considered to overestimate the background level of
aﬂatoxins in peanuts and peanut butter, especially the upper bound estimates. For peanuts and peanut
butter, 87% and 64%, respectively, of the AFT concentrations were left-censored. Moreover, around
66% of the samples were reported from only two European countries. Thus, the data set may not be
representative of aﬂatoxins on the European market.
The mean value of aﬂatoxins in peanuts is also inﬂuenced by some high values, and insufﬁcient
information was available in the EFSA Chemical Occurrence database, to separate peanut samples that
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were not subject to sorting or any other physical treatment from peanuts that are intended for direct
human consumption. Therefore, all available peanut samples were used in the exposure assessment.
Although it is expected that the majority of samples referred to peanuts for direct human
consumption, this may lead to an overestimation of the exposure.
No data were available regarding consignments that were not shipped to the EU due to levels exceeding
the current ML of 4 lg/kg but that would have been placed on the EU market if a higher ML was in place.
Data were instead generated by a simulation approach. The approach relied on the assumption that the
proportion of non-compliant samples (based on the reported data) would remain the same after the
increase of the ML. The calculated conﬁdence intervals indicated that the approach may lead to either an
over- or underestimation by approximately 10–15%. This introduces some uncertainty into the assessment.
Processing could only be partially taken into account, as limited occurrence data on roasted
peanuts and peanut butter were included in the exposure assessment. On the other hand, effects of
other processing methods, such as during manufacturing of peanut sauce or peanut oil could not be
addressed because of lack or limited data. This introduces uncertainty into the exposure assessment.
Before matching the consumption data to the corresponding occurrence data, eating occasions for
foods that may contain peanuts were identiﬁed and amounts were converted to the corresponding amount
of peanuts and peanut butter. Assumptions applied for this conversion may however not be accurate and
representative of all possible recipes and commercial products. Furthermore, it cannot be excluded that
peanuts or peanut butter have been used as a minor or exceptional ingredient of other composite foods.
This conversion is therefore to be considered as an approximation rather than an accurate calculation.
The total diet has not been taken into account in the exposure assessments, but only the exposure
from peanuts ready-to-eat, peanut butter, and processed products thereof. Since consumers of
peanuts and peanut butter represent on average 7% (range: 0–36%) of the total population, exposure
estimates for AFT in peanuts, peanut butter and processed products thereof was calculated for
consumers only. Considering that most consumption surveys covered only few days, the mean
consumption of consumers only, is most likely overestimated. On the other hand, a reliable exposure
assessment for highly exposed consumers was not possible due to the low number of consumers in
most dietary survey and age classes. This introduces additional uncertainty to the assessment.
Approximate estimations for the adult population indicated that for high consumers, exposures may be
underestimated by a fold-factor between 2 and 4, although it is not clear whether this ratio is also
applicable to the most exposed age classes such as adolescents and other children.
Based on these considerations, the CONTAM Panel concluded that there is substantial uncertainty in
the exposure assessment.
3.6.3. Model input (parameters)
There are no prescribed ﬁxed ofﬁcial methods for the analysis of aﬂatoxins in peanuts and
laboratories can use any appropriate method of analysis, provided it can be demonstrated in a traceable
manner that they fulﬁl the requirements according to Commission Regulation (EC) No 401/2006. This
may have added to the uncertainty in the analytical results but only to a minor extent.
3.6.4. Other uncertainties
The CONTAM Panel used the cancer potencies calculated by JECFA at its 83rd meeting. The liver
cancer potencies were calculated using an epidemiological study where the lowest exposure group had
an estimated exposure of 12 ng AFB1/kg bw (FAO/WHO, 1999). The potencies were expressed as the
liver cancer cases per 100,000 person years per ng aﬂatoxin. Applying these potency estimates for
AFB1 exposure of around 1 ng/kg bw per day and below implies an extrapolation outside the dose
range. However, considering that AFB1 is a carcinogen showing a linear dose–response in the range of
low doses tested in experimental studies (FAO/WHO, 2017), the CONTAM Panel concluded that this
extrapolation is appropriate, but is uncertain at very low doses and might overestimate the risk.
The cancer potencies were calculated by JECFA for both HBsAg+ and HBsAg– individuals. The
cancer potency for HBsAg– individuals is based on relatively few cases and is therefore more uncertain
than the estimated potency for HBsAg+ subjects.
The interaction between aﬂatoxin and hepatitis C is unknown and has not been taken into account,
which might underestimate the risk.
The CONTAM Panel assumed that the cancer potency of AFT is equal to that of AFB1. Given that
AFB1 is the most potent aﬂatoxin, this might overestimate the risk.
Use of UB cancer potencies may cause an overestimation of the cancer incidence.
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3.6.5. Summary of uncertainties
In Table 7, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment on effect
on public health of a possible increase of the ML for AFT from 4 to 10 lg/kg in ‘peanuts and processed
products thereof’, intended for direct human consumption or use as an ingredient in foodstuffs, is
large. The assessment is more likely to overestimate than to underestimate the additional risk.
4. Conclusions
4.1. General
Aﬂatoxins are mycotoxins produced primarily by the fungi A. ﬂavus and A. parasiticus.
A. parasiticus produces AFB1, AFB2, AFG1 and AFG2, whereas A. ﬂavus mainly produces AFB1 and
AFB2. However, A. ﬂavus isolates producing AFG1 and AFG2 also have been identiﬁed. These fungi are
especially found in areas with a hot and humid climate. AFB1 is the most frequently found aﬂatoxin in
contaminated samples and the three others are generally not reported in the absence of AFB1. AFT
refers to the sum of these four aﬂatoxins.
Aﬂatoxins have primarily been detected in imported foods such as peanuts, tree nuts, dried fruit,
spices, crude oil, cocoa beans, maize and rice. Processes such as heating, roasting and baking can reduce
the levels of aﬂatoxins but cannot completely eliminate the toxins. Extraction and reﬁning of oil can
reduce the levels of aﬂatoxins to less than 1 lg/kg even from highly contaminated samples of peanuts.
4.2. Occurrence/Exposure
• To estimate the occurrence of aﬂatoxins in peanuts and processed products thereof, EFSA used
a data set containing 8,095 samples for peanuts, 472 samples of peanut butter and
14 samples of peanut oil. Samples for peanut oil were all left-censored.
Table 7: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment on
effect on public health of a possible increase of the maximum level for ‘aﬂatoxin total’
from 4 to 10 lg/kg in peanuts and processed products thereof, intended for direct human
consumption or use as an ingredient in foodstuffs
Sources of uncertainty Direction
Same proportion of samples exceeding the current and the suggested increased maximum level +(a)
Resampling of occurrence data by bootstrapping +/
Limited occurrence data in peanut butter and peanut oil +/
Use of lower bound/upper bound data for ‘aﬂatoxin total’ +/
Mean value of ‘aﬂatoxin total’ in peanuts inﬂuenced by some high values, potentially being
removed from or not placed on the market
+
Conversion of foods that may contain peanuts into the corresponding amount of peanuts and
peanut butter
+/
Assessment for consumers only, while most consumption surveys cover few days +
Reliable assessment for highly exposed consumers was not possible 
Extrapolating cancer risk outside dose range +
Estimated cancer potency for hepatitis B surface antigen-subjects is more uncertain because based
on relatively few cases
+/
Cancer potency for aﬂatoxin B1 applied to ‘aﬂatoxin total’ +
Use of upper bound cancer potencies +
Possible interaction between aﬂatoxin and hepatitis C 
(a): + = uncertainty with potential to cause overestimation of exposure/risk;  = uncertainty with potential to cause
underestimation of exposure/risk.
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• The highest concentrations of AFT were found in peanuts with a mean value of 2.65/3.56 lg/
kg (LB/UB estimates) and a maximum concentration of 1,429 lg/kg. A total of 87% of the
samples were left-censored and 7% of the samples had a concentration higher than the
current ML of 4 lg/kg.
• Compared to the ﬁndings in peanuts, concentrations of AFT in peanut butter were lower with a
mean value of 1.47/1.92 lg/kg (LB/UB estimates) and a maximum value of 407 lg/kg. Also,
the number of left-censored samples was lower (64%) and 5% of the samples had a
concentration higher than the current ML of 4 lg/kg.
• Contribution of the individual aﬂatoxins to the AFT concentrations varied, but the major
contributor was identiﬁed as AFB1. On average, AFB1 represented 61% of the AFT MB
concentration for samples containing less than 1 lg/kg, and up to 78% for samples containing
more than 10 lg/kg.
• Based on a simulation by bootstrapping, it is anticipated that changing the ML from 4 to
10 lg/kg for peanuts will increase the mean LB estimates by a factor of 1.75 and the mean UB
estimates by a factor of 1.56. Although such a simulation could not be carried out for peanut
butter, it was assumed that the increase of aﬂatoxin levels in peanut butter would be
proportional to the increase anticipated for peanuts.
• Due to time constraints, an assessment of the total chronic dietary exposure to AFT
(considering all food sources) was not considered feasible. Furthermore, considering that
extraction and reﬁning of oil may reduce the concentrations of aﬂatoxins considerably, that the
ML under this assessment does not apply to peanut oil and that available occurrence data for
peanut oil were all left-censored, peanut oil was not included in the exposure assessment.
• Since consumers of peanuts and peanut butter represent on average 7% (range: 0–36%) of
the total population, exposure estimates for AFT in peanuts, peanut butter and processed
products thereof was calculated for consumers only.
• Assuming the current market situation with the ML of 4 lg/kg, mean chronic exposure
estimates for consumers only, ranged from 0.04 (lowest LB estimate) to 2.74 (highest UB
estimate) ng/kg bw per day. If the ML is changed to 10 lg/kg, it is expected that these
exposure estimates may increase up to 0.07 and 4.28 ng/kg bw per day, respectively. The
highest exposures were calculated for adolescents and other children.
• Due to the low number of consumers in most dietary surveys and age classes, a reliable
exposure assessment for highly exposed consumers was not possible. Approximate estimations
for the adult population indicated that exposure of high consumers may be two to four times
higher compared to the exposure of average consumers. However, it is not clear whether this
ratio is also applicable to the most exposed age classes such as adolescents and other children.
4.3. Risk characterisation
• AFB1 is a genotoxic compound and potent liver carcinogen in animals and humans. In
experimental animals, AFG1 is also carcinogenic, whereas there is limited evidence for
carcinogenicity of AFB2 and inadequate evidence for carcinogenicity of AFG2.
• The CONTAM Panel used the cancer potencies estimated by JECFA in 2016. The cancer
potencies were estimated to be 0.017 (mean) and 0.049 (95% UB) per 105 person years per
ng/kg bw for HBsAg– individuals and 0.269 (mean) and 0.562 (95% UB) per 105 person years
per ng/kg bw for HBsAg+ individuals.
• The cancer risk was estimated based on the mean cancer potency estimates and a prevalence of
HBsAg+ of 0.01%, as well as on the UB potency estimates and a prevalence of HBsAg+ of 5.61%.
• Under the scenario of the current ML, the cancer risk was estimated to range between
0.001 and 0.213 aﬂatoxin-induced cancers per year per 100,000 persons. Under the scenario
of the increased ML, it ranged between 0.001 and 0.333 aﬂatoxin-induced cancers per year
per 100,000 persons.
• According to the WHO Guideline for drinking-water quality, an excess lifetime cancer risk of
105 or less is considered to be of low risk for public health and, assuming a lifetime
expectancy of 70 years, this corresponds to a yearly excess cancer risk of 0.014 additional
cancer cases per 100,000 subjects. Comparing the estimated aﬂatoxin-induced cancers
calculated under the current ML scenario with this yearly excess cancer risk, a higher risk for
consumers of peanuts and peanut butter is identiﬁed in some surveys. The calculated cancer
risks indicate that an increase of the ML would further increase the risk by a factor of 1.6–1.8.
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5. Recommendations
• Considering that the last full risk assessment by the CONTAM Panel was carried out in 2007
and that elevated aﬂatoxin levels were observed in some food commodities originating from
European countries, a full risk assessment would be appropriate.
• Knowledge on contamination levels of consignments that were not shipped to the EU due to
exceedance of the current ML but would have been shipped if a higher ML was in place, would
be needed when assessing the effect on the risk for public health of a possible increase of an
ML in the future.
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AFB1 aﬂatoxin B1
AFB2 aﬂatoxin B2
AFG1 aﬂatoxin G1
AFG2 aﬂatoxin G2
AFM1 aﬂatoxin M1
AFM2 aﬂatoxin M2
AFT aﬂatoxin total
AIC Akaike information criterion
ALARA as low as reasonably achievable
BMD benchmark dose
BMDL benchmark dose lower conﬁdence limit
bw body weight
CCCF Codex Committee on Contaminants in Food
CI conﬁdence interval
CONTAM EFSA Panel on Contaminants in the Food Chain
DON deoxynivalenol
FD ﬂuorescence detection
GST glutathione S-transferase
HBsAg hepatitis B surface antigen
HPLC high-performance liquid chromatography
IARC International Agency for Research on Cancer
IPCS International Programme on Chemical Safety
JECFA Joint FAO/WHO Expert Committee on Food Additives
LB lower bound
LC left-censored
LOD limit of detection
LOQ limit of quantiﬁcation
MB middle bound
ML maximum level
MOE margin of exposure
MS mass spectrometry
MS/MS tandem mass spectrometry
N Number of samples/surveys
p probability of non-compliance with the maximum level
p’ probability of a concentration between 4 and 10 lg/kg when non-compliant
with the current maximum level
P50 50th percentile
P95 95th percentile
SOP standard operational procedure
UB upper bound
WG Working Group
WHO World Health Organization
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Appendix A – EFSA guidance documents applied for the risk assessment
The following EFSA guidance documents pertaining to risk assessment were followed for the
development of the risk assessment:
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to a harmonised approach for risk assessment of substances which
are both genotoxic and carcinogenic. EFSA Journal 2005;3(10):282, 33 pp. https://doi.org/
10.2903/j.efsa.2005.282
• EFSA (European Food Safety Authority), 2007. Guidance of the Scientiﬁc Committee on a
request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal
2007;5(1):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: general
principles. EFSA Journal 2009:7(5);1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2010. Standard sample description for food and feed.
EFSA Journal 2010;8(1):1457, 54 pp. https://doi.org/10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.
org/10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food
Consumption Database in Intakes Assessment. EFSA Journal 2011;9(3):2097, 34 pp. https://
doi.org/10.2903/j.efsa.2011.2097
• EFSA Scientiﬁc Committee 2011. Scientiﬁc Opinion on genotoxicity testing strategies applicable
to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/
10.2903/j.efsa.2011.2379
• EFSA Scientiﬁc Committee 2012. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579
• EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10(5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S,
Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck
D, Aerts M, Bodin L, Davis A, Edler L, Gundert-Remy U, Sand S, Slob W, Bottex B, Abrahantes
JC, Marques DC, Kass G and Schlatter JR, 2017. Update: Guidance on the use of the
benchmark dose approach in risk assessment. EFSA Journal 2017;15(1):4658, 41 pp. https://
doi.org/10.2903/j.efsa.2017.4658
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Appendix B – Dose–response models ﬁtted by JECFA to the data of Yeh
et al. (1989)
Curves show the number of primary hepatocellular carcinoma cases per person years in function of the dose
(ng/kg bw per day) for HBsAg positive (red) and HBsAg negative (blue) cases (see Section 1.3.1 and FAO/WHO,
2017 for further details).
Figure B.1: Dose–response models ﬁtted by JECFA to the data of Yeh et al. (1989)
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Annex A – Occurrence data submitted to EFSA and inﬂuence of increasing
the maximum level on dietary exposure
Annex A can be found in the online version of this output (‘Supporting information’ section): http://
onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5175/abstract
Description: The annex is an excel ﬁle which represents tables (from Table A.1 to A.6) on
aﬂatoxin occurrence and the inﬂuence of increasing the maximum level on dietary exposure.
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